Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
Masayoshi HarigaiKevin WinthropTsutomu TakeuchiTsu-Yi HsiehYi-Ming ChenJosef S SmolenGerd-Rüdiger R BurmesterChad WallsWen-Shuo WuChristina DicksonRan LiaoMark C GenovesePublished in: RMD open (2021)
HBV reactivation can occur among RA patients treated with DMARDs, including baricitinib, with prior HBV exposure. Our data suggest that such patients should be monitored for HBV DNA during treatment and might be treated safely with the use of antiviral therapy as needed. The risk of HBV reactivation in patients with HBsAg treated with baricitinib is unknown.
Keyphrases
- hepatitis b virus
- rheumatoid arthritis
- liver failure
- newly diagnosed
- clinical trial
- end stage renal disease
- chronic kidney disease
- ejection fraction
- disease activity
- prognostic factors
- randomized controlled trial
- interstitial lung disease
- stem cells
- circulating tumor
- systemic lupus erythematosus
- patient reported outcomes
- systemic sclerosis
- data analysis
- patient reported
- artificial intelligence
- double blind
- nucleic acid